8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                   ----------


                                    FORM 8-K

                                 CURRENT REPORT
                     Pursuant to Section 13 Or 15(D) of The
                         Securities Exchange Act of 1934


         Date of report (Date of earliest event reported): May 29, 2003



                              ANTARES PHARMA, INC.
                             ---------------------
               (Exact Name of Registrant as Specified in Charter)

         Minnesota                 0-20945                  41-1350192
         ---------                 -------                  ----------
      (State or Other           (Commission              (I.R.S. Employer
       Jurisdiction              File Number)            Identification No.)
     of Incorporation)


               707 Eagleview Boulevard, Suite 414, Exton, PA     19341
               --------------------------------------------------------
               (Address of Principal Executive Offices)      (Zip Code)

       Registrant's telephone number, including area code: (610) 458-6200


                                 Not Applicable
          -------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)



Item 9.           Regulation FD Disclsoure.

     On May 29, 2003, Antares Pharma, Inc. issued a press release regarding its
presentation at the Friedman Billings Ramsey 7th Annual Technology and Growth
Investor Conference. A copy of the press release issued is attached hereto as
Exhibit 99.1

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.

(c)      Exhibits.

         99.1        Press Release dated May 29, 2003.



                                    SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  May 29, 2003                              ANTARES PHARMA, INC.



                                                 By /s/ Lawrence M. Christian
                                                    ----------------------------
                                                    Lawrence M. Christian
                                                    Chief Financial Officer



                                  EXHIBIT INDEX

          99.1         Press Release dated May 29, 2003.

EX-99.1

                                                                    EXHIBIT 99.1

[LOGO OF
ANTARES PHARMA]



Contact Information

Dr. Roger Harrison          CEO and President                     (610) 458-6200
Lawrence M. Christian       CFO and Vice President - Finance      (610) 458-6200
Jay M. Green                Managing Director, Duncan Capital     (212) 581-5150


              ANTARES PHARMA TO PRESENT AT FRIEDMAN BILLINGS RAMSEY
              7TH ANNUAL TECHNOLOGY AND GROWTH INVESTOR CONFERENCE

Exton, Pennsylvania - May 29, 2003 - Antares Pharma, Inc. (Nasdaq: ANTR) is
scheduled to present at the Friedman Billings Ramsey 7/th/ Annual Technology and
Growth Investor Conference on Thursday, May 29, 2003, at 10:40 am ET. The
conference will be held at the Millennium Broadway Hotel in New York City. The
Company will be presenting information regarding its drug delivery technology
platforms, including needle-free and mini-needle injection systems and gel
formulation technology. Financial information and business projections,
including the Company's projection that the sale price of its reusable
needle-free device will be $50 in 2005 (compared to $1,000 in 1976) and the
Company's projection that its revenues will increase to more than $175 million
in 2008 (compared to $3.1 million in 2003), will also be presented. The
Company's reusable needle-free devices are designed to be used for a minimum of
two years in their current applications. The presentation will be webcast live
(audio with slide presentation) and may be accessed at
www.twst.com/econf/mm/fbr2/antr.html.

About Antares Pharma

     Antares Pharma develops pharmaceutical delivery systems, including
needle-free and mini-needle injection systems and transdermal gel technologies.
These delivery systems improve both the efficiency of drug therapies and the
patient's quality of life. The Company's needle-free injection systems for the
delivery of insulin and growth hormone are currently available in more than 20
countries. The Company's transdermal gel products for hormone replacement
therapy have been licensed to partners in the United States, Europe and Asia
Pacific. The most advanced of these are entering Phase III clinical development.
In addition, Antares Pharma has several products under development and is
conducting ongoing research to create new products that combine various elements
of the Company's technology portfolio. Antares Pharma has corporate headquarters
in Exton, Pennsylvania, with research and development facilities in Minneapolis,
Minnesota, and Basel, Switzerland.

     Statements included in this press release that are not historical in nature
are "forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. The Company cautions readers that forward-looking
statements are subject to certain risks and uncertainties, which could cause
actual results to differ materially and which are identified from time to time
in the Company's reports filed with the U.S. Securities and Exchange Commission.
Antares Pharma claims the protection of the Safe Harbor for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995.

     For more information, visit Antares Pharma's web site at
www.antarespharma.com. Information included on the Company's website is not
incorporated herein by reference or otherwise.